Ginkgo Bioworks Among Five in $58.76B Point-of-Care Diagnostics Market Growing 10%
Ginkgo Bioworks is named among five leading companies driving a $58.76B global point-of-care diagnostics market growing nearly 10% annually. Venture capital investments in digital health reached $4B in Q1, the highest first-quarter inflow since 2021, as backers shift from drug discovery to clinical-grade, decentralized testing platforms.
1. Point-of-Care Diagnostics Market Growth
The global point-of-care diagnostics market reached $58.76 billion in 2026 and is expanding at nearly 10% annually. Projections estimate the sector will hit $114.65 billion by 2035 as AI integration, miniaturized biosensors, and cloud connectivity compress testing turnaround from days to minutes.
2. Ginkgo Bioworks among Top Innovators
Ginkgo Bioworks is cited as one of five companies at the center of the structural shift toward decentralized clinical-grade testing platforms. Inclusion reflects investor confidence in its potential to support accessible diagnostic solutions beyond traditional hospital labs.
3. Investor Capital Influx
Digital health startups attracted $4 billion in venture funding during Q1 2026, marking the strongest first-quarter total since late 2021. Average deal sizes have climbed to multi-year highs as backers prioritize faster, lower-cost care delivery models.
4. Outlook for Ginkgo Bioworks
The ongoing realignment of diagnostics presents Ginkgo Bioworks with opportunities to expand into point-of-care solutions. Continued market expansion and growing demand for decentralized testing could translate into new partnerships and revenue streams.